PREDICTION OF RESPONSE TO TAXANE/ANTHRACYCLINE-CONTAINING CHEMOTHERAPY IN BREAST CANCER

• 1. 两种抗SPARC抗体用于预测对化学疗法的反应的用途 [P] . 中国专利： CN102460168B . 2015.05.20
• 2. 两种抗SPARC抗体用于预测对化学疗法的反应的用途 [P] . 中国专利： CN102460168A . 2012-05-16
• 3. PREDICTION OF BREAST CANCER RESPONSE TO TAXANE-BASED CHEMOTHERAPY [P] . 欧洲知识产权局专利： EP2041307A2 . 2009-04-01

  机译： 预测乳腺癌对基于TAXANE的化学疗法的反应

• 4. Prediction of Breast Cancer Response to Taxane-Based Chemotherapy [P] . 美国专利： US2009239223A1 . 2009-09-24

  机译： 紫杉烷类化学疗法对乳腺癌反应的预测

• 5. PREDICTION OF BREAST CANCER RESPONSE TO TAXANE-BASED CHEMOTHERAPY [P] . 世界知识产权组织专利： WO2008006517A2 . 2008-01-17

  机译： 预测乳腺癌对基于TAXANE的化学疗法的反应

• 1. Prediction of Response to Neoadjuvant Chemotherapy in Egyptian Patients with Locally Advanced Breast Cancer: The Evolving Role of Tumour Infiltrating Lymphocytes (TILs) [J] . Manal M. El-Mahdy, Riham A. Ibrahim, Radwa M. Hamed, 癌症治疗（英文） . 2020,第004期
• 2. Clinical Implications of HER-2 and P53 in Taxane-Based and Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer [J] . Xiaolan Wang, Fan Yao, Nan Liu, 癌症生物学与医学（英文版 ） . 2008,第006期
• 3. Early prediction of pathological outcomes to neoadjuvant chemotherapy in breast cancer patients using automated breast ultrasound [J] . Xinguang Wang, Ling Huo, Yingjian He, 中国癌症研究（英文版） . 2016,第005期
• 4. A Predictive Model for Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Using Machine Learning [J] . Isaac Kim, Kwanbum Lee, Seung Ah Lee, 乳腺癌（英文） . 2021,第004期
• 5. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy. [J] . Yonemori K, Katsumata N, Kaneko M, Breast cancer research and treatment. . 2007,第3期
• 6. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy [J] . Kan Yonemori, Noriyuki Katsumata, Masayuki Kaneko, Breast Cancer Research and Treatment . 2007,第3期
• 7. HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy [J] . HumbertO., CochetA., RiedingerJ.-M., European Journal of Nuclear Medicine and Molecular Imaging . 2014,第8期
• 8. Breast MRI radiomics for the pre-treatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients [C] . Karen Drukker, Iman El-Bawab, Alexandra Edwards, SPIE Conference on Computer-Aided Diagnosis . 2019
• 9. Breast Cancer Spatial Heterogeneity in Near-Infrared Spectra and the Prediction of Neoadjuvant Chemotherapy Response [D] . Santoro, Ylenia 2012
• 10. Chemotherapy Response Assay Test and Prognosis for Breast Cancer Patients Who Have Undergone Anthracycline- and Taxane-Based Chemotherapy [O] . Anbok Lee, Woosung Lim, Byung-In Moon, 2011
• 11. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. [O] . Bonnefoi, H., Piccart, M., Bogaerts, J., 2011

• 1. Unfavorable Pathological Complete Response Rate of Neoadjuvant Chemotherapy Epirubicin plus Taxanes for Locally Advanced Triple-negative Breast Cancer [J] . Yi YIN ,Pin ZHANG ,Bing-he XU . 华中科技大学学报（医学）（英德文版） . 2013,第002期
• 2. 微通道中含氮杂环化合物的硝化反应研究 [C] . Liu yangyihong ,刘阳艺红 ,Li bindong . 2016年全国功能精细化学品绿色制造及应用技术交流会 . 2016
• 3. MRI多参数联合Ki67对局部进展期乳腺癌新辅助化疗后病理反应的预测价值 [A] . 王彦龙 . 2020